Slow Capital Inc. Buys 410 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Slow Capital Inc. raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,765 shares of the biopharmaceutical company’s stock after acquiring an additional 410 shares during the quarter. Regeneron Pharmaceuticals makes up 1.3% of Slow Capital Inc.’s portfolio, making the stock its 17th largest holding. Slow Capital Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,093,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the stock. International Assets Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth $127,489,000. KBC Group NV lifted its holdings in shares of Regeneron Pharmaceuticals by 296.7% during the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after purchasing an additional 102,198 shares during the period. Icon Wealth Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 18,342.0% during the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $684.71 on Tuesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The stock has a market capitalization of $75.24 billion, a P/E ratio of 16.94, a PEG ratio of 1.59 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The business’s fifty day moving average price is $727.19 and its 200 day moving average price is $936.01.

Analyst Ratings Changes

REGN has been the subject of a number of analyst reports. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Evercore ISI cut their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,006.71.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.